Skip to content

Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain

Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00699114
Enrollment
350
Registered
2008-06-17
Start date
2007-06-30
Completion date
2009-12-31
Last updated
2011-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

Pain, Analgesics, Molar, Third, Acetaminophen, Paracetamol, Ibuprofen, Codeine, Placebo

Brief summary

The purpose of this placebo controlled clinical trial is to evaluate the dose response relationship of ibuprofen in doses from 400 mg to 800 mg and paracetamol (acetaminophen)in doses from 500 mg to 1000 mg compared with paracetamol (acetaminophen)1000 mg plus codeine 60 mg on acute postoperative pain after surgical removal of impacted third molars.

Detailed description

Acetaminophen (paracetamol) and related aspirin-like drugs have traditionally been used for pain control of minor to moderate postoperative pain. Gradually traditional non-steroidal anti-inflammatory drugs (NSAIDs) have become more popular as analgesics due to assumed superior therapeutic effects and aggressive marketing campaigns orchestrated by the pharmaceutical industry. Ibuprofen is a widely used analgesic both in non-prescription and prescription doses. A dose-response relationship for low ibuprofen doses is shown. Evidence of a progressing dose response relationship for moderate (i.e. 400 mg) to higher doses is scarce. A possible analgesic ceiling effect has been suggested for doses above 400 mg, although a correlation between given ibuprofen doses above 400 mg and patient serum levels is shown. However, it may be questioned if the plasma concentration of ibuprofen is an important determinator of analgesic drug efficacy. A higher dose is more likely to influence the duration of analgesic effect rather than the peak analgesic effect. There are few clinical trials investigating the dose-response relationship of increasing ibuprofen doses and paracetamol doses. To our knowledge no published study has investigated the dose-response relationship of ibuprofen and paracetamol in the same trial with a negative (i.e. placebo) and a positive (i.e. best standard analgesic treatment) control group.

Interventions

DRUGPlacebo

Lactose as powder in gelatine capsules, single dose

DRUGIbuprofen 400 mg

Ibuprofen 400 mg as powder in gelatine capsules, single dose

DRUGIbuprofen 600 mg

Ibuprofen 600 mg as powder in gelatine capsules, single dose

Ibuprofen 800 mg as powder in gelatine capsules, single dose

DRUGParacetamol (acetaminophen) 500 mg

Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose

Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose

DRUGParacetamol (acetaminophen) 1000 mg + codeine 60 mg

Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose

Sponsors

University of Oslo
CollaboratorOTHER
Ullevaal University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients of both sexes referred for surgical removal of impacted third molars, due to symptoms or after being advised to do so by their dentist. * Persons of both sexes (ASA type I). * Females who are not pregnant or plan conception. * Persons who have not used analgesics for 3 days prior to the day of surgery. * Persons without known active ulcus or gastrointestinal bleeding. * Persons without any known hypersensitivity for NSAIDs. * Persons under no other continuous drug treatment than contraceptives. * Caucasian origin. * Persons with at least moderate postoperative pain as defined by subjective score on a verbal rating scale after surgical removal of third molars.

Exclusion criteria

* Patients with surgery time exceeding 60 minutes * Peroperative complications such as profuse bleeding or perforation to the maxillary sinus requiring additional drug treatment during or after the surgical removal of the third molar. * Postoperative complications such as extended bleeding, nausea and regurgitation during the observation period. * Smoking before taking the test-drug or during the observation period.

Design outcomes

Primary

MeasureTime frame
Sum Pain Intensity Score(SPI)3 hour observation period

Secondary

MeasureTime frame
Sum Pain Intensity Difference Score (SPID)3 hours
Sum Pain Intensity Score (SPI)6 hours
Maximum Pain Intensity Difference Score (MAXPID)Unknown, calculated variable
Time to Maximum Pain Intensity Difference ScoreUnknown, calculated variable
Self-reported Occurrence of Adverse Effects3 hours

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026